**Non Patient-Specific Standing Order for the Administration of the**

**Pfizer-BioNTech Updated COVID-19 Vaccine (2023-2024 Formula) for Persons**

**6 Months to 4 Years of Age (Updated 10/18/2023)**

**Purpose:** To reduce morbidity and mortality from COVID-19 by administering the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) vaccination as permitted by the policy and order sections of this Order.

**Policy:** Under this non patient-specific standing order, [insert clinical staff titles] who are [employees, volunteers, [and/or] contractors] of the [Insert Organization Name] registered nurses (RNs) and pharmacists authorized to administer vaccines pursuant to a certificate of administration from the Department of Education and under non-patient specific standing orders in New York State and who are certified in cardio-pulmonary resuscitation, may administer the Moderna Updated COVID-19 Vaccine (2023-2024 Formula) to individuals ages 6 months to 4 years, as follows:

1. Nurses can administer vaccines to individuals aged 6 months to 4 years,
2. Pharmacists can administer COVID vaccine to those aged 3 years to 4 years,

as permitted by its Biologics License Application (BLA) approval or Emergency Use Authorization, as applicable, by the U.S. Food and Drug Administration (FDA), state and federal laws, Executive Orders, COVID-19 Public Health Readiness and Emergency Preparedness (PREP) Act declarations, and the recommendations of the Advisory Committee on Immunization Practices (ACIP).

The 2023–2024 Pfizer formulation has been updated as a monovalent vaccine based on the Omicron XBB.1.5 sublineage of SARS-CoV-2 and will be referred to as the “Pfizer COVID-19 Vaccine (2023-2024 Formula)” in this standing order.

Pfizer-BioNTech COVID-19 bivalent vaccine is no longer permitted to be used in any circumstance.

**NOTE:** Pharmacists and registered nurses must follow the requirements set forth in 8 NYCRR sections 63.9 & 64.7 respectively, including providing patients with requisite information, maintaining adequate records and adhering to reporting requirements.

**Procedure:** This standing order is for use of Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) multidose vials for persons 6 months to 4 years of age administered intramuscularly.

1. Assess children 6 months to 4 years of age *who are NOT moderately to severely immunocompromised* for eligibility for Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) based on the following criteria and administer dose(s) according to the table below:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **COVID-19 Vaccination history prior to updated (2023-2024 Formula)** | **Number of Pfizer-BioNTech COVID-19 (2023-2024 Formula) doses indicated** | **Dosage** | **Vaccine vial cap and label border colors** | **Interval between doses** |
| Unvaccinated | 3 | 0.3 mL/3 ug  | Multidose vial with yellow cap and yellow label border | Dose 1Dose 2 at least 3-8 weeks after dose 1Dose 3 at least 8 weeks after dose 2 |
| 1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine  | 2 | 0.3 mL/3 ug  | Multidose vial with yellow cap and yellow label border | Dose 2 at least 3-8 weeks after dose 1.Dose 3 at least 3-8 weeks after dose 2. |
| 2 previous doses of any Pfizer-BioNTech COVID-19 Vaccine | 1 | 0.3 mL/3ug | Multidose vial with yellow cap and yellow label border | Complete series:Dose 3 at least 8 weeks after Dose 2 |
| 3 or more doses of Pfizer-BioNTech Vaccine NOT including at least 1 dose of 2023-2024 COVID-19 Vaccine | 1 | 0.3 mL/3ug | Multidose vial with yellow cap and yellow label border | Give 1 dose at least 8 weeks (2 months) after the previous dose. |
| 3 or more doses of Pfizer-BioNTech Vaccine INCLUDING at least 1 dose of 2023-2024 COVID-19 Vaccine | 0 |  |  | No further doses are indicated |

Notes:

An 8 week interval between the first and second COVID-19 vaccine might be optimal for some people as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.

People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 month to 4 years and those who are moderately or severely immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional circumstances a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination with the same vaccine due to a contraindication.

Children who have received 1 Moderna and 1 Pfizer-BioNTech vaccines of any formulation need to receive a third dose of either Moderna vaccine or Pfizer-BioNTech vaccine s at least 8 weeks after the second dose.

For more information, please see CDC’s Interim Clinical Considerations: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

1. Assess individuals aged 6 months to 4 years *who are moderately to severely immunocompromised* and administer Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) dose(s) according to the table below:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **COVID-19 Vaccination history prior to updated (2023-2024 Formula)** | **Number of Pfizer-BioNTech COVID-19 (2023-2024 Formula) doses indicated** | **Dosage** | **Vaccine vial cap and label border colors** | **Interval between doses** |
| Unvaccinated | 3 | 0.3 mL/3ug | Multidose vial with yellow cap and yellow label border | Dose 1Dose 2 at least 3 weeks after dose 1Dose 3 at least 8 weeks after dose 2 |
| 1 previous dose any Pfizer-BioNTech COVID-19 Vaccine | 2 | 0.3 mL/3ug  | Multidose vial with yellow cap and yellow label border | Dose 2 at least 3 weeks after dose 1.Dose 3 at least 8 weeks (2 months) after dose 2. |
| 2 doses any Pfizer-BioNTech COVID-19 Vaccine | 1 | 0.3 mL/3ug | Multidose vial with yellow cap and yellow label border | Dose 3 at least 8 weeks after dose 2 |
| 3 or more doses any Pfizer-BioNTech COVID-19 Vaccine NOT including at least 1 dose of 2023-2024 COVID-19 vaccine | 1 | 0.3 mL/3ug | Multidose vial with yellow cap and yellow label border | At least 8 weeks after last dose |
| 3 or more doses of Pfizer-BioNTech Vaccine, INCLUDING at least one dose of 2023-2024 COVID-19 vaccine | 1 | 0.3 mL/3ug | Multidose vial with yellow cap and yellow label border | -People who are moderately or severely immunocompromised have the option to receive 1 additional dose at least 8 weeks (2 months) following the last recommended dose-Further additional doses may be administered informed by the clinical judgement of a health care provider and personal preference and circumstances-Any further additional doses should be administered at least 8 weeks (2months) after the last COVID-19 vaccine dose |

Notes:

People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 month to 4 years and those who are moderately or severely immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional circumstances a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination with the same vaccine due to a contraindication.

.

Children who have received 1 Moderna and 1 Pfizer-BioNTech vaccines of any formulation need to receive a third does of either Moderna vaccine or Pfizer-BioNTech vaccine s at least 8 weeks after the second dose.

Additional Clinical Considerations

* Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) may be simultaneously administered with other routinely recommended vaccines.
* Revaccinate persons who received doses of COVID-19 vaccine prior to or during hematopoietic cell transplantation (HCT) or chimeric antigen receptor T-cell (CAR-T-cell) therapy, following the current COVID-19 vaccination schedule. Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy

For more information, please see CDC’s Interim Clinical Considerations: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

1. Screen for contraindications and precautions
	1. **Contraindications:** History of a severe allergic reaction (e.g., anaphylaxis) after a previous dose of Pfizer-BioNTech vaccine to a component of the Pfizer-BioNTech COVID-19 vaccine.
	2. **Precautions:**
		1. A diagnosed non-severe allergy to a component of the COVID-19 vaccine.
		2. Non-severe, immediate (onset less than 4 hours) allergic reaction after administration of a previous dose of COVID-19, if receiving the same vaccine type.
		3. Moderate to severe acute illness, with or without fever
		4. Multisystem inflammatory syndrome in children (MIS-C).
		5. Myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine.
2. Provide information on the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) and obtain consent.
3. Prior to vaccine administration:
4. Inform each patient or a patient’s legal guardian, as applicable, of the risks, benefits, and alternatives of receiving the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula).
5. As the vaccination provider, you must communicate to the recipient or their caregiver, information consistent with the [information for recipients and caregivers](https://labeling.pfizer.com/ShowLabeling.aspx?id=16351&Section=PPI) prior to the individual receiving Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) including: **(1)** FDA has approved the use of the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) for ages 12 years and older; there is an Emergency Use Authorization in place for ages 6 months-11years. **(2)** The recipient or their caregiver has the option to accept or refuse Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula); **(3)** The significant known and potential risks and benefits of Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula), and the extent to which such risks and benefits are unknown; and **(4)** Information about available alternative vaccines and the risks and benefits of those alternatives.
6. **For those aged 6 months to 4 years of age:** Provide each patient’s legal guardian, as applicable, the package insert, or direct the individual to the website to [obtain the fact sheet](https://labeling.pfizer.com/ShowLabeling.aspx?id=16351&Section=PPI) for the EUA.
7. Obtain consent to administer the vaccine from the patient or the patient’s legal guardian, as applicable following the clinic’s or pharmacy’s policies for consent. [Insert how the Organization will be documenting consent and what forms will be used].
8. Provide necessary information on receiving the next dose of vaccine, if applicable.

5. Prepare to administer vaccine

1. Administration of multi-dose vials
	1. Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) multi-dose vials do not contain preservatives. Strict adherence of aseptic technique during administration must be followed.
	2. **Carefully inspect the vial prior to preparation**. The Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) multi-dose dose vial for children 6 months to 4 years of age, has a **yellow cap** and a **yellow label border**.
	3. Inspect the vaccine in the vial. Prior to mixing the vial, the thawed vaccine may contain white to off-white opaque amorphous particles.
	4. For multi-dose vials with yellow caps and yellow labels, dilute prior to use.

a. Add 1.1 mL of sterile 0.9% Sodium Chloride injection, USP, into the vaccine vial.

b. Before removing the needle form the vial, equalize vial pressure by withdrawing air into the

 c. Record the date and time of dilution on the vial label.

* 1. Before use, mix the vial by inverting vaccine vial gently 10 times. Do not shake.
	2. After mixing, the vaccine should appear as an off-white suspension with no visible particles. Do not use if vaccine is discolored or contains particulate matter. Call the manufacturer and the New York State Department of Health (NYSDOH) if this occurs.
	3. Using aseptic technique, cleanse the vial stopper with a single-use antiseptic swab, and withdraw 0.3 mL of the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula). If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume. Do not pool excess vaccine from multiple vials.
		1. Administer vaccine:
1. For children 6 months to 2 years of age, use a 22-25 gauge, 1 inch needle. Give the vaccination in the vastus lateralis muscle in the anterolateral thigh.
2. For children 2 through 4 years of age, use a 22-25 gauge, 1 inch needle. Give the vaccination in the deltoid muscle in the upper arm.
3. Administer Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) by intramuscular injection, 0.3mL/3ug.

7. Document Vaccination

Document each patient’s vaccine administration information and follow-up in the following places:

**Medical Record System** **(including CDMS, as applicable) :** Ensure that the patient’s name, the date the vaccine was administered, the name of the vaccine, the manufacturer and lot number, the vaccination site and route, address of administering site, and the name and title of the authorized person administering the vaccine, and the date it was given to the patient is documented in the patient’s medical record or on a separate form retained by the authorized vaccinator who has administered the immunization, and in a retrievable format available to the State Education Department and the patient. If vaccine was not administered, record the reason(s) for non-receipt of the vaccine (e.g., medical contraindication, refusal). Documentation must be completed within 24 hours of administration. This information, whether in a medical record or separately kept, must be recorded and maintained in accordance with 8 NYCRR section 29.2 (a) (3).

**Signed Certificate of Immunization** (given to the patient’s parent or legal guardian)**:** Record the patient’s name, date of vaccination, name/location of the administering clinic or pharmacy, administering nurse or pharmacist, name of vaccine, manufacturer and lot number, and recommendations for future immunizations.

**New York State Immunization Information System (NYSIIS) and City Immunization Registry (CIR):** Report all doses administered to those 18 years of age and younger to NYSIIS or CIR within 24 hours of administration. Report all doses administered to those 19 years of age and older to NYSIIS and CIR after obtaining consent. With respect to NYSIIS, if the dose was documented in CDMS, then the NYSDOH shall transmit data from CDMS to NYSIIS.

1. Management of medical emergencies

A post vaccination observation period should be considered to monitor patients for the occurrence of immediate adverse reactions:

* 30 minutes:
	+ History of non-severe, immediate (less than 4 hours) allergic reaction after a previous dose of COVID-19 vaccine
	+ History ofallergy-related contraindication to a different type of COVID-19 vaccine
	+ History of anaphylaxis after non-COVID-19 vaccines or injectable therapies
* 15 minutes: All other people

Be prepared for management of a medical emergency related to the administration of vaccine by maintaining written copies of the standing orders and protocols for administration of epinephrine and diphenhydramine. RNs or pharmacists shall be responsible for having emergency anaphylaxis treatment agents, related syringes and needles at the immunization site, including at least 3 epinephrine prefilled syringes or autoinjectors appropriate for age, H1 antihistamine, blood pressure cuff, and a stethoscope and timing device to assess pulse. To prevent syncope, vaccinate patients while they are seated or lying down and assess for signs of syncope such as extreme paleness, sweating, coldness of the hands and feet, nausea, lightheadedness, dizziness, weakness or visual disturbances.

For more information, please see:

* Interim Considerations: Preparing for the Potential Management of Anaphylaxis at COVID-19 Vaccination sites at: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html>
* CDC’s General Best Practice Guidelines for Immunization, “Preventing and Managing Adverse Reactions,” at <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/adverse-reactions.pdf>
* Immunization Action Coalition’s “Medical Management of Vaccine Reactions in Adults in a Community Setting” at <https://www.immunize.org/catg.d/p3082.pdf>.
* Immunization Action Coalition’s “Medical Management of Vaccine Reactions in Children and Teens in a Community Setting” at <https://www.immunize.org/catg.d/p3082a.pdf>
1. Reporting of adverse events
2. Report the following information associated with the administration of Pfizer-BioNTech COVID‑19 Vaccine (2023-2024 Formula) of which they become aware to Vaccine Adverse Events Electronic Reporting System (VAERS) including:
3. Vaccine administration errors whether or not associated with an adverse event
4. Serious adverse events (irrespective of attribution to vaccination)[[1]](#footnote-2)
5. Cases of myocarditis or pericarditis after vaccine
6. Cases of Multisystem Inflammatory Syndrome in children and adults
7. Cases of COVID-19 that result in hospitalization or death
8. Any additional adverse events and revised safety requirements per the Food and Drug Administration’s conditions for use of an authorized vaccine

Complete and submit reports to VAERS online at https://vaers.hhs.gov/reportevent.html or by calling 1-800-822-7967. To the extent feasible,

1. Storage and Handling of Vaccine for Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula)
2. Storage of Multidose Vials Prior to Use
	1. Pfizer-BioNTech COVID-19 vaccines (2023-2024 Formula) contain preservative-free ultra-frozen suspension that must be stored at appropriate temperatures to preserve efficacy. Consult CDC, NYSDOH and Pfizer guidance on storage and handling of Pfizer-BioNTech COVID-19 vaccines.
	2. Pfizer-BioNTech COVID-19 vaccine multidose vials and prefilled syringes received ultra-frozen on dry ice may be stored ultra-frozen between -90°C to -60°C (-130°F to -76° F) until expiration date printed on the vials, prefilled syringes, and cartons.
	3. Unpunctured vial can be stored in the refrigerator between 2⁰C to 8⁰C (36⁰F to 46⁰F) for up to 10 weeks prior to first use, not to exceed the expiration date.  The 10-week refrigerated expiry date should be recorded on the carton at the time of transfer.
	4. Unpunctured vials can be stored between 8C and 25C (46F and 77F) for up to 12 hours before the first puncture or use.
	5. Do not store vials and prefilled syringes at -25°C to -15°C (-13°F to 5°F).
	6. Once thawed, unpunctured vials and prefilled syringes should not be refrozen. If vaccine is received thawed, it must be stored in the refrigerator between 2⁰C to 8⁰C (36⁰F to 46⁰F) for up to 2 hours. During storage, minimize exposure to room light, and avoid exposure to direct sunlight and ultraviolet light.

**Order:** I am hereby prescribing this non patient-specific order to administration of Moderna COVID‑19 Vaccine (2023-2024 Formula) on [insert dates and locations].Specifically, [insert staff titles] who are employees, volunteers, or contractors of the [Insert Organization] may administer Pfizer-BioNTech COVID‑19 Vaccine, as permitted by its BLA approval or its Emergency Use Authorization (EUA), as applicable, state and federal laws, Executive Orders, COVID-19 Public Health Readiness and Emergency Preparedness (PREP) Act declarations, ACIP recommendations, and the CDC’s and New York State’s Vaccination Program.

This non patient-specific order shall remain in effect for the vaccination of any individuals as set forth herein, beginning on [insert date] through [insert date]. In the event that I discontinue this non patient-specific order prior to [insert end date as listed above], notice of such discontinuance shall be provided to those [Insert Organization] employees and contractors permitted to execute under this Order via [insert how employees, volunteers, and contractors will be notified of a discontinuance].

Signature: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_

Name of Physician: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Title: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Institution: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

NYS License No.: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Effective Date of Order: \_\_\_\_\_\_\_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Serious adverse events are defined as: (1) Death; (2) A life-threatening adverse event; (3) Inpatient hospitalization or prolongation of existing hospitalization; (4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; (5) A congenital anomaly/birth defect; or (6) An important medical event that based on appropriate medical judgement may jeopardize the individual and may require medical or surgical intervention to prevent one of the outcomes listed above. [↑](#footnote-ref-2)